AR098997A2 - Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación - Google Patents

Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación

Info

Publication number
AR098997A2
AR098997A2 ARP140104956A ARP140104956A AR098997A2 AR 098997 A2 AR098997 A2 AR 098997A2 AR P140104956 A ARP140104956 A AR P140104956A AR P140104956 A ARP140104956 A AR P140104956A AR 098997 A2 AR098997 A2 AR 098997A2
Authority
AR
Argentina
Prior art keywords
dosage unit
constipation
analogue
analog
suitable excipient
Prior art date
Application number
ARP140104956A
Other languages
English (en)
Inventor
Ueno Ryuji
L Patchen Myra
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23293447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR098997(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of AR098997A2 publication Critical patent/AR098997A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/23—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)

Abstract

Se describe una unidad de dosificación para tratar la constipación en un paciente humano. La unidad de dosificación comprende un análogo de prostaglandina halogenado y un excipiente farmacéuticamente adecuado. La unidad de dosificación alivia la constipación sin efectos colaterales sustanciales. Reivindicación 1: Una unidad de dosificación para usar con el fin de aliviar o prevenir la constipación en un paciente humano que comprende un análogo de prostaglandina (PG) representado por la fórmula (1) y/o sus tautómeros, y un excipiente farmacéuticamente adecuado, caracterizada porque la unidad de dosificación contiene dicho análogo de PG en el rango de aprox. 6 - 96 mg; en donde A¹ y A² son átomos de halógeno iguales o diferentes y B es -COOH, incluyendo sus sales, ésteres o amidas farmacéuticamente aceptables. Reivindicación 3: La unidad de dosificación de acuerdo con la reivindicación 1, caracterizada porque dicho análogo de PG está presente en el rango de aprox. 24 - 72 mg. Reivindicación 7: La unidad de dosificación de acuerdo con la reivindicación 1, caracterizada porque dicho excipiente farmacéuticamente adecuado es un ácido graso de cadena mediana.
ARP140104956A 2001-11-14 2014-12-30 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación AR098997A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33131601P 2001-11-14 2001-11-14

Publications (1)

Publication Number Publication Date
AR098997A2 true AR098997A2 (es) 2016-06-22

Family

ID=23293447

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP020104349A AR037524A1 (es) 2001-11-14 2002-11-13 Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
ARP140104956A AR098997A2 (es) 2001-11-14 2014-12-30 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación
ARP190100714A AR117404A2 (es) 2001-11-14 2019-03-21 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP020104349A AR037524A1 (es) 2001-11-14 2002-11-13 Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP190100714A AR117404A2 (es) 2001-11-14 2019-03-21 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación

Country Status (15)

Country Link
US (3) US8097653B2 (es)
EP (2) EP1443938B1 (es)
JP (2) JP4852229B2 (es)
AR (3) AR037524A1 (es)
AT (1) ATE522218T1 (es)
BR (1) BR0214075A (es)
CA (1) CA2464420C (es)
CY (1) CY1115856T1 (es)
DK (2) DK1443938T3 (es)
ES (2) ES2368729T3 (es)
HK (1) HK1155649A1 (es)
LU (1) LU92826I2 (es)
PT (2) PT2298314E (es)
TW (1) TWI331920B (es)
WO (1) WO2003041716A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US8114911B2 (en) * 2002-10-23 2012-02-14 Sucampo Ag Prostaglandin compounds for the treatment of obesity
MXPA05006981A (es) * 2002-12-27 2005-12-14 Sucampo Ag Derivados de prostaglandinas para el tratamiento de la molestia abdominal.
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI387454B (zh) * 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) * 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
RU2468800C2 (ru) * 2005-04-12 2012-12-10 Сукампо Аг Комбинированное применение производного простагландина и ингибитора протонового насоса для лечения желудочно-кишечных заболеваний
US7985770B2 (en) * 2006-01-24 2011-07-26 Sucampo Ag Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
CA2637274C (en) * 2006-01-24 2013-06-04 R-Tech Ueno, Ltd. Soft-gelatin capsule formulation
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
WO2011035142A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5350141A (en) 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
GB1581886A (en) 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
DE3873007T2 (de) * 1987-10-02 1992-12-03 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2027814C (en) 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
DE69130586T2 (de) * 1990-05-01 1999-06-17 R Tech Ueno Ltd Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
JP2938579B2 (ja) * 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
EP0503887B1 (en) * 1991-03-14 1996-08-28 R-Tech Ueno Ltd. Promotion of wound-healing with 15-keto-prostaglandin compounds
DK0554794T3 (da) * 1992-02-04 1999-04-26 Eisai Co Ltd Aminobenzoesyrederivater
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
KR19990036322A (ko) * 1996-06-10 1999-05-25 류지 우에노 엔도텔린길항제
DE19717005A1 (de) * 1997-04-23 1998-10-29 Kennametal Inc Spannfutter für Rundlaufwerkzeuge
ATE401894T1 (de) 1997-11-28 2008-08-15 Sucampo Ag Verwendung von 15-keto-prostaglandin-e verbindungen als endothelin antagonisten
US6492417B1 (en) 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
CN1268623C (zh) 1999-10-15 2006-08-09 苏坎波公司 组合物和使该组合物稳定的方法
EP1267883B1 (en) 2000-04-06 2009-06-17 Sucampo AG Bile secretion promoting composition for liver transplantation containing a 15-keto-prostaglandin
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
TWI324589B (en) 2001-05-18 2010-05-11 Sucampo Ag Halogenated bioactive lipid compound
CA2458471C (en) 2001-08-31 2012-07-31 Sucampo Ag Prostaglandin analogs as chloride channel opener
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
MXPA05006981A (es) 2002-12-27 2005-12-14 Sucampo Ag Derivados de prostaglandinas para el tratamiento de la molestia abdominal.

Also Published As

Publication number Publication date
PT1443938E (pt) 2011-09-27
EP1443938B1 (en) 2011-08-31
TWI331920B (en) 2010-10-21
DK1443938T3 (da) 2011-09-26
TW200300091A (en) 2003-05-16
AR037524A1 (es) 2004-11-17
DK2298314T3 (en) 2014-12-01
US8097653B2 (en) 2012-01-17
LU92826I2 (fr) 2015-11-24
WO2003041716A1 (en) 2003-05-22
ES2524369T3 (es) 2014-12-05
CA2464420A1 (en) 2003-05-22
CA2464420C (en) 2011-12-13
US20120088824A1 (en) 2012-04-12
US20130143958A1 (en) 2013-06-06
JP2011201905A (ja) 2011-10-13
AR117404A2 (es) 2021-08-04
BR0214075A (pt) 2004-09-28
JP4852229B2 (ja) 2012-01-11
HK1155649A1 (en) 2012-05-25
US8389542B2 (en) 2013-03-05
PT2298314E (pt) 2014-12-03
ES2368729T3 (es) 2011-11-21
CY1115856T1 (el) 2017-01-25
EP2298314B1 (en) 2014-09-03
US20030119898A1 (en) 2003-06-26
EP2298314A1 (en) 2011-03-23
JP2005513014A (ja) 2005-05-12
ATE522218T1 (de) 2011-09-15
EP1443938A1 (en) 2004-08-11

Similar Documents

Publication Publication Date Title
AR098997A2 (es) Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación
SE0202462D0 (sv) Novel use
ES2190674T3 (es) Uso de n-alquil derivados de cadena larga de desoxinojirimicina para la fabricacion de un medicamento para el tratamiento de enfermedades de acumulacion de glucolipidos.
UY26782A1 (es) Derivados del benzotiazol
BR0210261A (pt) Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes
MXPA03010435A (es) Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
UY26977A1 (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgésicos
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
CO4960645A1 (es) Composicion farmaceutica de drogas antiinflamatorias no- esteroides y analogos de gaba y metodos para prevenir y tratar dano gastrointestinal, enfermedad inflamatoria del intestino irritable y sindrome de privacion del alcohol
HUP0401192A2 (hu) Fényérzékenyítő szer alkalmazása sebek kezelésére adható gyógyászati készítmény előállítására
NO20024772D0 (no) Percyquinnin, fremgangsmåte for dets fremstilling og dets anvendelse som et legemiddel
HUP0402422A2 (hu) Deuterizált szubsztituált pirazolil-benzolszulfonamid-származékok, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
NO20022442L (no) Legemidler for sykdommer i forbindelse med reduksjon i benmasse
SE0202429D0 (sv) Novel Compounds
ECSP045469A (es) El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
HUP0201284A2 (hu) Hatóanyagként kinazolindionszármazék kimáz inhibitort tartalmazó gyógyászati készítmények fibrózis megelőzésére vagy kezelésére
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
NO975726D0 (no) N-Hydroksyurea-derivater som anti-inflammatoriske midler
NO20031678L (no) Profylaktisk og terapeutisk middel for diabetiske komplikasjoner
ATE393152T1 (de) Phtalazine derivate mit angiogenesis inhibierender wirkung
HUP0202710A2 (hu) Vitronektin receptor antagonisták, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
PT1337246E (pt) Utilizacao de compostos de 6-dimetilaminometil-1-fenilciclohexano para terapia da incontinencia urinaria
SE9900190D0 (sv) New compounds

Legal Events

Date Code Title Description
FB Suspension of granting procedure